ArticleThe Lancet. Oncology2019
Risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer (Teenage and Young Adult Cancer Survivor Study): a population-based, cohort study.
Article in The Lancet. Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 6 syntheses or guidelines pooled it, 143 citations in OpenAlex.
- Risks of colorectal and extracolonic cancers following colorectal cancer: a systematic review and meta-analysis.JNCI cancer spectrum · 2025Pooled it
- The risk for subsequent primary lung cancer after cervical carcinoma: A quantitative analysis based on 864,627 cases.PloS one · 2024Pooled it
- Pooled it
- Risk of extracolonic second primary cancers following a primary colorectal cancer: a systematic review and meta-analysis.International journal of colorectal disease · 2022Pooled it
- Risk of second primary cancer among breast cancer patients: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Young Adult Cancer Survivorship: Recommendations for Patient Follow-up, Exercise Therapy, and Research.JNCI cancer spectrum · 2021Guideline
- A Mobile Instant Messaging-Delivered Psychoeducational Intervention for Cancer Caregivers: A Randomized Clinical Trial.JAMA network open · 2024Trial
- Age- and latency-specific patterns of subsequent malignant brain and other nervous system tumors after cancer diagnosed before age 40 years.Cancer causes & control : CCC · 2026Article
- Long-term cardiac morbidity in adolescent and young adult survivors of classical Hodgkin lymphoma: the British Columbia experience.Haematologica · 2026Article
- Health Behaviors in Adolescent and Young Adult (AYA) Childhood Cancer Survivors: Prevalence, Determinants, and Comparison With Population Controls.Cancer medicine · 2026Article
- Distinct epigenetic alterations and accelerated mitotic aging define second primary breast cancers.Scientific reports · 2026Article
- Transitions Within and Use of Outpatient Primary and Oncology Care in Survivors of Adolescent and Young Adult-Onset Cancers.JCO oncology practice · 2026Article
- Subsequent primary neoplasm risk among survivors of cancer in adolescence and young adulthood: a population-based study from Alberta, Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026Article
- Cancer Screening Uptake and Usual Source of Care Among Hispanic Survivors of Adolescent and Young Adult Cancer.Journal of adolescent and young adult oncology · 2026Article
- Prognostic factors for 5 year relapse-free survivors following curative resection for stage II/III colorectal cancer.Surgery today · 2026Article
- Hospitalization for medical conditions in adolescent and young adult cancer survivors: a nationwide cohort study using the Netherlands Cancer Registry.Journal of cancer survivorship : research and practice · 2026Article
- Subsequent primary cancer risks for non-hereditary colorectal cancer survivors.EClinicalMedicine · 2026Article
- Sequential changes in conditional survival of patients following surgical resection of colorectal cancer and indicators for follow-up beyond 5 years.International journal of clinical oncology · 2026Article
- Subsequent risk of non-keratinocyte skin cancers in adult cancer survivors: a SEER-based cohort study.BMJ open · 2026Article
- Subsequent primary cancer incidence in cervical cancer survivors: insights from a comprehensive cohort study utilizing combined Japanese population-based cancer registries.Journal of gynecologic oncology · 2026Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundFew studies have investigated the risks of subsequent primary neoplasms after adolescent and young adult (AYA) cancer. We investigated the risks of specific subsequent primary neoplasms after each of 16 types of AYA cancer.
methodsThe Teenage and Young Adult Cancer Survivor Study is a population-based cohort of 200 945 survivors of cancer diagnosed when aged 15-39 years in England and Wales from Jan 1, 1971, to Dec 31, 2006. The cohort was established using cancer registrations from the Office for National Statistics and the Welsh Cancer registry. Follow-up was from 5-year survival until the first occurrence of death, emigration, or study end date (Dec 31, 2012). In this analysis, we focus on the risk of specific subsequent primary neoplasms after 16 types of AYA cancer: breast; cervical; testicular; Hodgkin lymphoma (female); Hodgkin lymphoma (male); melanoma; CNS (intracranial); colorectal; non-Hodgkin lymphoma; thyroid; soft-tissue sarcoma; ovarian; bladder; other female genital; leukaemia; and head and neck cancer. We report absolute excess risks (AERs; per 10 000 person-years) and cumulative incidence of specific types of subsequent primary neoplasm after each type of AYA cancer.
findingsDuring the 2 631 326 person-years of follow-up (median follow-up 16·8 years, IQR 10·5-25·2), 12 321 subsequent primary neoplasms were diagnosed in 11 565 survivors, most frequently among survivors of breast cancer, cervical cancer, testicular cancer, and Hodgkin lymphoma. AERs of any subsequent primary neoplasms were 19·5 per 10 000 person-years (95% CI 17·4-21·5) in survivors of breast cancer, 10·2 (8·0-12·4) in survivors of cervical cancer, 18·9 (16·6-21·1) in survivors of testicular cancer, 55·7 (50·4-61·1) in female survivors of Hodgkin lymphoma, and 29·9 (26·3-33·6) in male survivors of Hodgkin lymphoma. The cumulative incidence of all subsequent primary neoplasms 35 years after diagnosis was 11·9% (95% CI 11·3-12·6) in survivors of breast cancer, 15·8% (14·8-16·7) in survivors of cervical cancer, 20·2% (18·9-21·5) in survivors of testicular cancer, 26·6% (24·7-28·6) in female survivors of Hodgkin lymphoma, and 16·5% (15·2-18·0) in male survivors of Hodgkin lymphoma. In patients who had survived at least 30 years from diagnosis of cervical cancer, testicular cancer, Hodgkin lymphoma in women, breast cancer, and Hodgkin lymphoma in men, we identified a small number of specific subsequent primary neoplasms that account for 82%, 61%, 58%, 45%, and 41% of the total excess number of neoplasms, respectively. Lung cancer accounted for a notable proportion of the excess number of neoplasms across all AYA groups investigated.
interpretationOur finding that a small number of specific subsequent primary neoplasms account for a large percentage of the total excess number of neoplasms in long-term survivors of cervical, breast, and testicular cancer, and Hodgkin lymphoma provides an evidence base to inform priorities for clinical long-term follow-up. The prominence of lung cancer after each of these AYA cancers indicates the need for further work aimed at preventing and reducing the burden of this cancer in future survivors of AYA cancer.
fundingCancer Research UK, National Institute for Health Research, Academy of Medical Sciences, and Children with Cancer UK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.